Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganciclovir
Drug ID BADD_D01003
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status Prescription; Discontinued
ATC Code J05AB06; S01AD09
DrugBank ID DB01004
KEGG ID D00333
MeSH ID D015774
PubChem ID 135398740
TTD Drug ID D05ARP
NDC Product Code 12806-6941; 59651-108; 24208-535; 72969-084; 12869-803; 71052-685; 65977-0062; 51754-2500; 42023-173
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H13N5O4
CAS Registry Number 82410-32-0
SMILES C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tension19.06.02.005--Not Available
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Torsade de pointes02.03.04.005--Not Available
Transplant rejection12.02.05.022; 10.02.03.002--Not Available
Tremor17.01.06.002--
Trismus17.01.03.004; 15.05.04.004--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.05.02.001; 10.02.02.006--
Ventricular arrhythmia02.03.04.006--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vitreous disorder06.08.03.006--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wound dehiscence12.02.05.003--
Conjunctival hyperaemia06.04.01.004--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages